Vyne Therapeutics

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded on October 21, and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.

Journey Medical Corporation (NASDAQ: DERM) has acquired Molecule Stabilizing Technology (MST) franchise, including Amzeeq (minocycline) topical foam and Zilxi (minocycline) topical foam from VYNE Therapeutics Inc (NASDAQ: VYNE)  The transaction includes cash payments of $25 million and potential milestones of up to $450 million.

VYNE Therapeutics Offloads Its Topical Minocycline Assets To Journey Medical In $450M+ Deal

Transaction includes cash payments of $25 million and potential milestones of up to $450 million

VYNE Therapeutics Divests Topical Minocycline Assets

BRIDGEWATER, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that management will participate in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022.

VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event

Investors need to pay close attention to for VYNE Therapeutics (VYNE) stock based on the movements in the options market lately.

Do Options Traders Know Something About VYNE Therapeutics (VYNE) Stock We Don't?

Arbutus Biopharma

Ensysce Biosciences

Genius Brands

Are these Reddit penny stocks on your watchlist right now? The post 4 Penny Stocks That Are Trending on Reddit Right Now and Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks That Are Trending on Reddit Right Now and Why

Allied Esports Entertainment Inc

Cumberland Pharma

Harbor Custom Development, Inc.

Spark Networks

Outlook Therapeutics Inc

PEDEVCO

Party City Holdco

Selecta Biosciences

Corporate insiders buy penny stocks & these 10 are getting purchased in December 2021. The post 10 Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Penny Stocks To Buy In December According To Insiders

VYNE Therapeutics (VYNE) stock price predictions are heating up on Monday with one analyst setting a high goal for the company to reach. The post VYNE Stock Price Predictions: Why One Analyst Sees VYNE Therapeutics Going to $7 appeared first on InvestorPlace.

VYNE Stock Price Predictions: Why One Analyst Sees VYNE Therapeutics Going to $7

Yes, even insiders buy penny stocks & here are 5 getting scooped up in December 2021. The post 5 Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy In December According To Insiders

The stock price of Vyne Therapeutics Inc (NASDAQ: VYNE) increased by over 9% pre-market today. This is why it happened.

Vyne Therapeutics Stock (VYNE): Why The Price Increased Today

BRIDGEWATER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

VYNE Therapeutics Inc. (VYNE) CEO Dave Domzalski on Q3 2021 results - Earnings Call Transcript

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of -5.88% and -12.51%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Lags Revenue Estimates

Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies

VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Results support continued progression of VYN201 development program for autoimmune skin diseases Results support continued progression of VYN201 development program for autoimmune skin diseases

Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study

BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021

VYNE Therapeutics Inc (NASDAQ: VYNE) announced preclinical data for VYN201, its pan-bromodomain and extra-terminal (BET) inhibitor. The data showed that VYN201 significantly reduced the expression of several key pro-inflammatory cytokines relevant to Th17-mediated autoimmune diseases in an animal model and an ex vivo human tissue study.

VYNE Therapeutics' BET Inhibitor Shows Encouraging Preclinical Action

BRIDGEWATER, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced preclinical data showing that its pan-bromodomain and extra-terminal (“BET”) inhibitor, VYN201, significantly reduced the expression of several key pro-inflammatory cytokines relevant to Th17-mediated autoimmune diseases in an animal model and an ex vivo human tissue study. The pathogenesis of many autoimmune diseases is linked to the proliferation and activity of Th17 cells, which include several diseases that VYNE is evaluating for its VYN201 program.

Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies

Renowned Experts to Support VYNE's Strategy of Developing Novel Treatments for Immunological and Inflammatory diseases

VYNE Therapeutics Announces Formation of Scientific Advisory Board

Important milestone achieved as part of the Company's new corporate strategy to develop treatments for immuno-inflammatory diseases

VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

BRIDGEWATER, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the first patient has been enrolled in a Phase 3 study in China evaluating AMZEEQ® (minocycline) topical foam, 4% in moderate to severe acne. The study is being conducted by the Company's partner, Cutia Therapeutics (“Cutia”), for the purposes of seeking regulatory approval for AMZEEQ in China.

VYNE Therapeutics Announces its China Partner's Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne

BRIDGEWATER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference, to take place September 27th – 30th.

VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference

BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13th - 15th.

VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference

VYNE Therapeutics Inc. (VYNE) CEO Dave Domzalski on Q2 2021 Results - Earnings Call Transcript

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0.00% and -31.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

Shares of VYNE Therapeutics (NASDAQ:VYNE) fell 15.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 57.32% year over year to ($0.35), which were in line with the estimate of ($0.35).

News for Vyne Therapeutics Stock (VYNE)